The Opioid Treatment Surge Act (HR 3105 / S 1662, 116th Congress) would impose an annual fee, for ten years after the Act’s enactment, on opioid drug manufacturers based on their market share of opioid drugs. All companies that manufactured opioids between January 1, 1999 and the date of the Act’s enactment would be included under this Act. Notably, opioid drugs sold to treat opioid addiction, or to treat patients with cancer or in hospice, would be exempt. Funds raised by this fee would be placed in a general fund and used for the prevention and treatment of substance abuse.
The ongoing opioid crisis in the US is estimated to cause 130 deaths per day. A number of legislative proposals, including this Act, seek to reduce rates of dependence and overdose on opioids.